BDA
The sold-out Bermuda Business Development Agency’s (BDA) Bermuda Risk Summit was declared an immense success, with over 80 overseas delegates in attendance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005995/en/
The immediate economic impact of the event, which had a total of 350 delegates, including lodging, transportation, food and beverage, retail and recreation was estimated at over one million dollars, and supported around 200 jobs. Based on market feedback, dozens of additional visitors flew to Bermuda for business meetings around the event, bringing additional economic impacts to the island.
The Hon. Jason Hayward, JP, MP, Minister of Economy and Labour, who attended the event, said, “Congratulations to the BDA for organising such a successful inaugural event which had a positive impact on Bermuda’s economy and community. Bermuda remains the world’s risk capital, and for decades, Bermuda based insurers have been leaders in the global reinsurance industry. It was a pleasure to meet and hear first-hand updates from some of the world’s foremost risk and regulatory experts. The Government along with the Bermuda Monetary Authority (BMA) plays a critical role in the success of Bermuda’s Insurance Industry and remains a partner, committed to supporting the growth of the industry.”
David Hart, BDA CEO, said, “We received fantastic feedback for taking a leadership role in organising the first in-person risk event since 2019. A running theme across the event was how great it was to get off zoom and see each other again in person after such a long absence. Our hope was always that this event would provide an opportunity for Bermuda’s risk industry to start charting a way forward together and meet prior to mid-year renewal season. We look forward to building on this success by making our second annual event on March 6-8, 2023, even bigger and better next year.”
The Risk Summit was kicked off by a ‘sea-side’ chat between Bermuda’s Premier, The Hon. David Burt, JP, MP, and Mr. Hart. In his remarks, Premier Burt said, “Thank you to all those who are visiting but thank you also to our risk industry who throughout this pandemic has been a bedrock of support inside of the community...The objective of this government as we move beyond the pandemic is to make sure that Bermuda maintains its leadership across the board and remains the most competitive place to deploy capital.”
The seaside chat was followed by a panel made up of global CEOs, including Albert Benchimol, President & CEO, Axis; Stephen Catlin, Chairman & CEO, Convex; Marc Grandisson, CEO, Arch Capital Group; Chris Schaper, CEO, AIG Re; and Megan Thomas, CEO, Hamilton Re. In his remarks, CEO panel moderator John Huff, CEO, of the Association of Bermuda Insurers and Reinsurers (ABIR) welcomed the three ABIR-sponsored Bermuda College students in the audience. Also in the audience was a contingent of risk and insurance students from Eastern Kentucky University who flew down especially for the event and to learn about Bermuda’s globally important risk industry.
Day two started off with breakfast keynote on terrorism risk from Julian Enoizi, CEO Pool Re, and was followed by panels featuring rating agencies, brokers, life, and a Florida Legislative Update. Day two was rounded off by an incredible keynote lunch featuring Aon President, Eric Andersen.
Our final day began with a keynote on Florida risk by Joseph Petrelli, President, Demotech, with panels on captives, cyber, InsurTech, and Insurance Linked Securities (ILS) following. Day 3 was closed out by remarks about an upcoming Bermuda ESG benchmarking survey by Miqdaad Versi, Head of ESG, Oxbow Partners, UK.
The BDA thanks our diamond sponsors, ABIR, Aon and EY, our gold sponsor Appleby, and our silver sponsors Ariel Re, Kirkland & Ellis, KPMG, and SiriusPoint. We were also fortunate to have Bermuda Brokers, Florida Insurance Council, Kettle, Meenan P.A., and Goslings as additional event sponsors. Our media partner was The Insurer. The Bermuda Risk Summit was a SafeKey event.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, relocate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005995/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom